An observational study in Metabolic Syndrome, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. Recruiting at 1 site in Italy. Open to participants aged 13 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-09-18.
Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Metabolic Syndrome with a site in Italy — 16 open to participants now, 18 under way, none of them phase 3. Metabolic Syndrome · Italy.
Among the 95 studies in Metabolic Syndrome with a site in Italy, this one is the 30th largest by planned enrollment of the 33 observational ones that give a count, is one of 4 that started in 2024, is one of 33 observational ones, reaches primary completion later than 4 of the 17 other live ones, and was the 85th registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →16 of the 95 studies in Metabolic Syndrome with a site in Italy are open now. Recruiting first, the newest first:
Catholic University of the Sacred Heart · Sites in Italy
Ages 18+
Dr. Schär AG / SPA · Sites in Italy
Ages 18–60
Catholic University of the Sacred Heart · Sites in Italy
Ages 18–80
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18–80
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Women only
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 13 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 7 · Phase 4 9
First in 1996; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is below the median of 196 across 497 observational studies indexed under Metabolic Syndrome.
Median enrollment 71 across the 62 interventional studies, 200 across the 33 observational. Of the 59 that completed or were terminated, 2 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 95 have an industry lead sponsor. The 10 most frequent:
Fondazione IRCCS Policlinico San Matteo di Pavia is the lead sponsor of 258 studies on the registry; 115 are open to participants now.
Fondazione IRCCS Policlinico San Matteo di Pavia has 1 study filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Metabolic Syndrome with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06801769Catholic University of the Sacred HeartStudy for the Identification of a Score to Assess Intrapancreatic Fat Through Eco-Elastography and Its Correlation With Metabolic Syndrome and Insulin-Secreting Cells. | 2026-12 |
| NCT07155473Fondazione Policlinico Universitario Agostino Gemelli IRCCSIdentification of a Score for the Assessment of Intrapancreatic Fat | 2026-12 |
| NCT05781269Istituto Auxologico ItalianoLong Term Effect of Very-low-calories Ketogenic Diet on Weight Control and Cardiovascular Brisk Factors (KETOHEART) | 2026-12-31 |
| NCT06647108ESIFood Supplement for Individuals with Metabolic Syndrome | 2027-01 |
| NCT07505277Dr. Schär AG / SPAStudy of the Effects of Food Formulations Containing Antioxidants, Prebiotic Fibers, and Oat Beta-glucans in Individuals at Risk of Metabolic Syndrome | 2027-02 |
Add all 5 to your calendar (.ics) → With an account.
Among the 95 studies in Metabolic Syndrome with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
MetS is a syndrome characterized by a combination of diabetes, hypertension and visceral obesity, altered blood lipids, beginning in childhood, leading to chronic disease in adulthood. Adult criteria for defining MetS require a minimum of 3 risk factors, listed in the NCEP ATP III (National Cholesterol Education Program, Adult Treatment Panel III, ATP III), they are hyperglycaemia, hypertriglyceridemia, low HDL-C, hypertension, obesity and increased waist circumference.
The pediatric definitions are described mainly by Cooks, Zimmet and de Ferranti are as well based on the presence of ≥ 3 symptoms: obesity (BMI) , waist circumference, glucose intolerance, dyslipidaemia (high triglycerides and/or low HDL-C), High BP. Pediatric criteria of MetS are not univocally defined and symptoms may be fluctuant in adolescent period, therefore the prevalence ranges from 4.2%13 to 9.2%. A number of researchers have used factor analysis of MetS components to develop a risk score to identify children at higher risk for developing MetS. Several MetS risk factors have origins during the prenatal and early postnatal period. In particular, it is known that preterm newborns are more prone to develop this condition once adults, but little is known about the adolescent transition, particularly, in Italy.
From 2008 - 2011, thirty-four full-term and 36 premature infants were studied, evaluating echocardiographic parameters and BNP concentrations during the first month of life. In this population, now adolescents, it was decided to measure BNP, both current and previous values, in order to verify whether this parameter can be associated with MetS and meet the need to identify high-risk children.
Adolescents affected by MetS were defined on the basis of the available literature: they must present ≥ 3 of the following signs: hyperglycaemia, dyslipidaemia (triglycerides and HDL-C), arterial hypertension, obesity (BMI and waist circumference). Other blood parameters were also evaluated as associated factors, such as white blood cell count, glycosylated haemoglobin, creatinine, urea nitrogen, and suPAR. Doppler echocardiography and tissue Doppler parameters, psychosocial variables (KIDSCREEN-10).
BNP has been shown to play a role not only in heart disease but also in adult patients with obesity, insulin resistance, and diabetes, all of which are present in MetS. Therefore, the primary objective is to assess whether BNP can be an index associated with adolescent MetS. The opportunity was taken to evaluate a population of premature and full-term adolescents. BNP was previously studied in the first month of life, and it is possible to establish a correlation with the adolescent situation. Therefore, the cohort of newborns who are now between 13 and 15 years of age will be recalled.
The data available in the literature and clinical experience suggest a prevalence of metabolic syndrome of between approximately 5 and 10%.
patients whose BNP concentration and echocardiographic parameters was analysed during their first month of life (2009-11) of life at Fondazione IRCCS Policlinico San Matteo
Inclusion Criteria:
Association of BNP with MetS in adolescent period
we define MetS when an adolescent presents 3 of the following symptoms: hyperglycemia (\>110 mg/dl), dyslipidemia (triglycerides \<= 120 mg/dl and/or HDL-C \< 60 mg/dl), High BP (systolic \>120 mmHg diastolic \>80 mmHg) , obesity (BMI \> 30 and waist circumference \> 0.5).
Time frame: December 2025
association of BNP in neonatal period and adolescents biomedical measurements
Time frame: December 2025
Association of adolescent BNP and MetS within categories of psychosocial variables (as identified by the KIDSCREEN-10 instrument) which are established to have a role in the development of MetS
Psychosocial data: KIDSCREEN-10 instrument: Self-report questionnaire for the assessment of adolescents' subjective health and health-related quality of life (HRQOL). The normalized score will be then categorized with a cut-off of 50.
Time frame: December 2025
Association of BNP in neonatal period with MetS
Time frame: December 2025
Plan to share: No
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Dec 2025, 19 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione IRCCS Policlinico San Matteo di Pavia →